Professor Gunhild Waldemar, director of the Danish Dementia Research Center (DDRC), was a guest speaker at the recent Second Congress of the European Academy of Neurology (EAN) in Copenhagen, and she encouraged researchers to work together to develop standardized guidelines for early diagnosis and treatment of Alzheimer’s disease (AD). She reinforced the notion that…
Boulder, Colorado-based Accera has completed enrollment for its Phase 3 NOURISH AD clinical trial of AC-1204 for the treatment of mild to moderate Alzheimer’s disease (AD). Top-line data should be reported later this year. AC-1204 is an orally administered therapy with the potential to improve dementia patients’ cognition and…
Researchers have found an association between fitness and blood flow to areas of the brain where the hallmark tangles and plaques of Alzheimer’s disease (AD) are typically detected. The study, “Cardiorespiratory fitness modifies the relationship between myocardial function and cerebral blood flow in older adults,” was published in the journal…
The UC Cures for Alzheimer’s Disease Initiative was launched recently by the University of California (UC) to accelerate the most promising Alzheimer’s disease research. Projects could be studies or proof-of-concept clinical trials to confirm a new imaging modality or biomarker. Sponsored by the UC Office of the President with a foundational…
Face recognition difficulties in Alzheimer’s patients have typically been attributed to underlying episodic and semantic memory impairment. Dr. Sven Joubert, Ph.D., from the Centre de recherche de l’Institut universitaire de gériatrie de Montréal, and colleagues have found that more than causing memory problems, Alzheimer’s also impairs visual face perception, a…
Oryzon Genomics recently announced the dosing of a first subject in its Phase 1 trial of oral LSD1-MAOB dual selective inhibitor ORY-2001, targeting memory loss and cognitive decline in Alzheimer’s disease. The single and multiple ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of ORY-2001 in healthy subjects. The trial is randomized, double-blind,…
Relatives and friends of people suffering from dementia may put their retirement savings at stake or sell assets as they increasingly face hard financial decisions to keep taking care of their loved ones. Most families have to cut back on spending, and many have to cut out basic necessity items, according to…
During the American Chemical Society annual meeting, leading international researchers shared promising findings of 24 studies that looked at the beneficial effects of natural products on brain health and on the prevention of Alzheimer’s and other neurodegenerative diseases. For the first time, the beneficial effects of pure maple syrup…
Blueberries, a “super fruit” known to decrease the risk of cancer and heart disease, may also be of benefit against Alzheimer’s disease, according to findings recently presented at the 251st National Meeting & Exposition of the American Chemical Society (ACS). Blueberries are loaded with antioxidants, which, according to researchers, could…
European scientists have demonstrated that a nutritional drink, Fortasyn Connect, does not benefit broad cognitive function to the degree expected, but it can help to conserve brain tissue and memory in early, or prodromal, Alzheimer’s disease patients. The clinical trial is part of the LipiDiDiet project, a large European study exploring the therapeutic and…
Get regular updates to your inbox.